Una formulacion de una capsula farmaceutica compuesta que comprende 1) una unidad independiente comprendiendo irbesartan o una de sus sales y 2) una unidad independiente comprendiendo un inhibidor de la hmg-coa reductasa o una de sus sales y un aditivo alcalino, en donde dichas unidades independientes se separan unas de otras dentro de la capsula; y su metodo de preparacion.

摘要

Disclosed are a pharmaceutical composite capsule formulation comprising 1) an independent irbesartan unit comprising irbesartan or a pharmaceutically acceptable salt thereof; and 2) an independent HMG-CoA reductase inhibitor unit comprising an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and an alkaline additive, wherein said independent units are separated from each other within a capsule, and a method for preparing the same. Designed to prevent an interaction between irbesartan and the HMG-CoA reductase inhibitor, the pharmaceutical composite capsule formulation is improved in stability and dissolution rate, and thus shows great bioavailability. In addition, the formulation is expected to guarantee high drug compliance owing to its small size, and therefore can be applied to the treatment of hypertension and hypercholesterolemia.